| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:ACSL5-ETV6 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: ACSL5-ETV6 | FusionPDB ID: 1514 | FusionGDB2.0 ID: 1514 | Hgene | Tgene | Gene symbol | ACSL5 | ETV6 | Gene ID | 51703 | 2120 |
| Gene name | acyl-CoA synthetase long chain family member 5 | ETS variant transcription factor 6 | |
| Synonyms | ACS2|ACS5|FACL5 | TEL|TEL/ABL|THC5 | |
| Cytomap | 10q25.2 | 12p13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | long-chain-fatty-acid--CoA ligase 5FACL5 for fatty acid coenzyme A ligase 5LACS 5arachidonate--CoA ligasefatty acid coenzyme A ligase 5fatty-acid-Coenzyme A ligase, long-chain 5long-chain acyl-CoA synthetase 5long-chain fatty acid coenzyme A ligase | transcription factor ETV6ETS translocation variant 6ETS variant 6ETS-related protein Tel1TEL1 oncogeneets variant gene 6 (TEL oncogene) | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q9ULC5 | P41212 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000354273, ENST00000354655, ENST00000356116, ENST00000369410, ENST00000393081, ENST00000433418, ENST00000479936, | ENST00000544715, ENST00000396373, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 6 X 6 X 5=180 | 21 X 24 X 6=3024 |
| # samples | 6 | 19 | |
| ** MAII score | log2(6/180*10)=-1.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(19/3024*10)=-3.99238681589013 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: ACSL5 [Title/Abstract] AND ETV6 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | |||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ACSL5 | GO:0001676 | long-chain fatty acid metabolic process | 24269233 |
| Tgene | ETV6 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 10514502 |
| Fusion gene breakpoints across ACSL5 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ETV6 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerKB3 | . | . | ACSL5 | chr10 | 114170393 | + | ETV6 | chr12 | 11992073 | + |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000354655 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 6629 | 1077 | 254 | 2272 | 672 |
| ENST00000393081 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 6655 | 1103 | 280 | 2298 | 672 |
| ENST00000433418 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 6628 | 1076 | 49 | 2271 | 740 |
| ENST00000356116 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 6628 | 1076 | 49 | 2271 | 740 |
| ENST00000354273 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 6627 | 1075 | 48 | 2270 | 740 |
| ENST00000369410 | ACSL5 | chr10 | 114170393 | + | ENST00000396373 | ETV6 | chr12 | 11992073 | + | 5858 | 306 | 164 | 1501 | 445 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >1514_1514_1_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000354273_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=740AA_BP=341 MTRDSSEQGRTGDTLGRPSACMDALKPPCLWRNHERGKKDRDSCGRKNSEPGSPHSLEALRDAAPSQGLNFLLLFTKMLFIFNFLFSPLP TPALICILTFGAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNGPCLGYRKPNQPY RWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKALV LIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFTSGTTGLQPIYWSRDDVAQWLKW AENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTP RPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESH PKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLW DYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKEPGQRLLFRFMKTPDEIMSGRTD -------------------------------------------------------------- >1514_1514_2_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000354655_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=672AA_BP=273 MNFLLLFTKMLFIFNFLFSPLPTPALICILTFGAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVF QRGLAVSDNGPCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAI VHIVNKADIAMVICDTPQKALVLIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFT SGTTGLQPIYWSRDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSI HTQPEVILHQNHEEDNCVQRTPRPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQ ESYPLSVSPMENNHCPASSESHPKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMV SVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKE -------------------------------------------------------------- >1514_1514_3_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000356116_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=740AA_BP=341 MTRDSSEQGRTGDTLGRPSACMDALKPPCLWRNHERGKKDRDSCGRKNSEPGSPHSLEALRDAAPSQGLNFLLLFTKMLFIFNFLFSPLP TPALICILTFGAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNGPCLGYRKPNQPY RWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKALV LIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFTSGTTGLQPIYWSRDDVAQWLKW AENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTP RPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESH PKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLW DYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKEPGQRLLFRFMKTPDEIMSGRTD -------------------------------------------------------------- >1514_1514_4_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000369410_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=445AA_BP=46 MLFPGASIVPECWLLVLIQNLGKEHFRKPVPPSPEDLSVICFTSGTTGLQPIYWSRDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLL TKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTPRPSVDNVHHNPPTIELLHRSRSPIT TNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESHPKPSSPRQESTRVIQLMPSPIMHPL ILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENFIRWEDKESKI -------------------------------------------------------------- >1514_1514_5_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000393081_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=672AA_BP=273 MNFLLLFTKMLFIFNFLFSPLPTPALICILTFGAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVF QRGLAVSDNGPCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAI VHIVNKADIAMVICDTPQKALVLIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFT SGTTGLQPIYWSRDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSI HTQPEVILHQNHEEDNCVQRTPRPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQ ESYPLSVSPMENNHCPASSESHPKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMV SVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKE -------------------------------------------------------------- >1514_1514_6_ACSL5-ETV6_ACSL5_chr10_114170393_ENST00000433418_ETV6_chr12_11992073_ENST00000396373_length(amino acids)=740AA_BP=341 MTRDSSEQGRTGDTLGRPSACMDALKPPCLWRNHERGKKDRDSCGRKNSEPGSPHSLEALRDAAPSQGLNFLLLFTKMLFIFNFLFSPLP TPALICILTFGAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNGPCLGYRKPNQPY RWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKALV LIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFTSGTTGLQPIYWSRDDVAQWLKW AENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTP RPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESH PKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLW DYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKEPGQRLLFRFMKTPDEIMSGRTD -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:/chr12:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ACSL5 | ETV6 |
| FUNCTION: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:17681178, PubMed:24269233, PubMed:22633490). ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells. {ECO:0000250, ECO:0000269|PubMed:17681178, ECO:0000269|PubMed:18806831, ECO:0000269|PubMed:19459852, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}. | FUNCTION: Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation. {ECO:0000269|PubMed:25581430}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Protein Structures |
| PDB and CIF files of the predicted fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Fusion protein PDB link (fusion AA seq ID in FusionPDB) | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | AA seq | Len(AA seq) |
| PDB file (212) >>>212.pdbFusion protein BP residue: 46 CIF file (212) >>>212.cif | ACSL5 | chr10 | 114170393 | + | ETV6 | chr12 | 11992073 | + | MLFPGASIVPECWLLVLIQNLGKEHFRKPVPPSPEDLSVICFTSGTTGLQ PIYWSRDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSP HSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNC VQRTPRPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDN MIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESHPKPSS PRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLS HREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENF IRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNII | 445 |
| 3D view using mol* of 212 (AA BP:46) | ||||||||||
 | ||||||||||
| PDB file (545) | ACSL5 | chr10 | 114170393 | + | ETV6 | chr12 | 11992073 | + | MNFLLLFTKMLFIFNFLFSPLPTPALICILTFGAAIFLWLITRPQPVLPL LDLNNQSVGIEGGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNG PCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQN RPEWIISELACYTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKA LVLIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGK EHFRKPVPPSPEDLSVICFTSGTTGLQPIYWSRDDVAQWLKWAENEFSLR PIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILF SPFFHPGNSIHTQPEVILHQNHEEDNCVQRTPRPSVDNVHHNPPTIELLH RSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQ ESYPLSVSPMENNHCPASSESHPKPSSPRQESTRVIQLMPSPIMHPLILN PRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAM PIGRIADCRLLWDYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLW GNHKNRTNMTYEKMSRALRHYYKLNIIRKEPGQRLLFRFMKTPDEIMSGR | 672 |
| PDB file (604) | ACSL5 | chr10 | 114170393 | + | ETV6 | chr12 | 11992073 | + | MTRDSSEQGRTGDTLGRPSACMDALKPPCLWRNHERGKKDRDSCGRKNSE PGSPHSLEALRDAAPSQGLNFLLLFTKMLFIFNFLFSPLPTPALICILTF GAAIFLWLITRPQPVLPLLDLNNQSVGIEGGARKGVSQKNNDLTSCCFSD AKTMYEVFQRGLAVSDNGPCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLL HKGYKSSPDQFVGIFAQNRPEWIISELACYTYSMVAVPLYDTLGPEAIVH IVNKADIAMVICDTPQKALVLIGNVEKGFTPSLKVIILMDPFDDDLKQRG EKSGIEILSLYDAENLGKEHFRKPVPPSPEDLSVICFTSGTTGLQPIYWS RDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDV LYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTP RPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRL SPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESHPKPSSPRQES TRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDL AYMNHIMVSVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENFIRWED KESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKEPG | 740 |
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted wild-type structures of two partner proteins from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
ACSL5_pLDDT.png |
ETV6_pLDDT.png  |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
ACSL5_ETV6_212_PAE.png (AA BP:46) |
ACSL5_ETV6_212_pLDDT.png (AA BP:46) |
ACSL5_ETV6_212_pLDDT_and_active_sites.png (AA BP:46) |
ACSL5_ETV6_212_violinplot.png (AA BP:46) |
Top |
Ramachandran Plot of Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| Fusion AA seq ID in FusionPDB and their Ramachandran plots |
| ACSL5_ETV6_212.png |
 |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Fusion AA seq ID in FusionPDB | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| 212 | 1.051 | 251 | 1.139 | 673.995 | 0.614 | 0.637 | 0.83 | 1.243 | 0.561 | 2.214 | 2.281 | Chain A: 9,11,12,13,14,16,17,18,20,21,23,24,25,26, 27,28,29,31,32,33,34,36,37,39,40,43,65,69,70,71,72 ,73,92,101,102,104,105,108,109,111,112,113,115,116 |
Top |
Potentially Interacting Small Molecules through Virtual Screening |
| The FDA-approved small molecule library molecules were subjected to virtual screening using the Glide. |
| Fusion AA seq ID in FusionPDB | ZINC ID | DrugBank ID | Drug name | Docking score | Glide gscore |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. |
| ZINC ID | DrugBank ID | Drug name | Drug type | SMILES | Drug group |
Top |
Biochemical Features of Small Molecules |
| ADME (Absorption, Distribution, Metabolism, and Excretion) of drugs using QikProp(v3.9) |
| ZINC ID | mol_MW | dipole | SASA | FOSA | FISA | PISA | WPSA | volume | donorHB | accptHB | IP | Human Oral Absorption | Percent Human Oral Absorption | Rule Of Five | Rule Of Three |
Top |
Drug Toxicity Information |
| Toxicity information of individual drugs using eToxPred |
| ZINC ID | Smile | Surface Accessibility | Toxicity |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| ACSL5 | CREB3, KIF11, FAM136A, COQ9, FBXO7, RNF4, RAB7A, SLC7A14, SLC35C2, AQP6, SLC10A1, PEX12, SLC16A7, TMEM14B, EPT1, FAM134C, SLC10A6, EBAG9, CAV2, ELK1, PAK1, PEBP1, PRKCB, PRKD1, SH2D3C, PDS5A, WDR5, |
| ETV6 | KAT5, GAB2, ETV6, GRB2, CRKL, ACTA1, HDAC9, FLI1, FBXL6, SKP1, L3MBTL1, IRF8, NCOR1, SIN3A, HDAC3, UBE2I, ELAVL1, PDGFRB, SUMO1, SOCS1, SOCS3, TRAF3, SOX2, HDAC6, PIN1, AP1M1, WDYHV1, LRP6, LRP5, NID2, ETV7, USP7, VPS26B, NFATC2, EGLN3, NKX2-1, TRAF2, AXIN1, ESR2, LMNA, TP53BP1, BRCA1, MDC1, KIAA1429, WWP2, ESR1, BRD4, NFE2L2, MAD2L1, B4GALT2, KLHL9, KLHL13, SUMO2, ARHGAP32, SEC16A, XPOT, PIAS2, CEP152, NUP214, NUP62, NUP98, SEC13, RBM11, ECH1, ZNF146, TRIP6, CEP85, NUP54, TAB3, ALMS1, CEP192, PPIL4, RQCD1, SDCCAG3, NUP88, TBL1Y, KIAA1671, C2orf44, GRPEL1, TNRC6C, MID1IP1, CYLD, ZMYM2, LIMD1, SPATA2, TNRC6B, TIMM13, FLOT1, LGALS3BP, FLOT2, HNRNPUL1, |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| ACSL5 |  |
| ETV6 |  |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to ACSL5-ETV6 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ACSL5-ETV6 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ACSL5 | C0003865 | Arthritis, Adjuvant-Induced | 1 | CTD_human |
| Hgene | ACSL5 | C0971858 | Arthritis, Collagen-Induced | 1 | CTD_human |
| Hgene | ACSL5 | C0993582 | Arthritis, Experimental | 1 | CTD_human |
| Tgene | ETV6 | C4015537 | THROMBOCYTOPENIA 5 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | ETV6 | C0023485 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | CTD_human |
| Tgene | ETV6 | C0040034 | Thrombocytopenia | 3 | CTD_human;GENOMICS_ENGLAND |
| Tgene | ETV6 | C0023480 | Leukemia, Myelomonocytic, Chronic | 2 | ORPHANET |
| Tgene | ETV6 | C1332965 | Congenital Mesoblastic Nephroma | 2 | ORPHANET |
| Tgene | ETV6 | C0006413 | Burkitt Lymphoma | 1 | ORPHANET |
| Tgene | ETV6 | C0013146 | Drug abuse | 1 | CTD_human |
| Tgene | ETV6 | C0013170 | Drug habituation | 1 | CTD_human |
| Tgene | ETV6 | C0013222 | Drug Use Disorders | 1 | CTD_human |
| Tgene | ETV6 | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Tgene | ETV6 | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Tgene | ETV6 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CGI;CTD_human;GENOMICS_ENGLAND |
| Tgene | ETV6 | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
| Tgene | ETV6 | C0038580 | Substance Dependence | 1 | CTD_human |
| Tgene | ETV6 | C0038586 | Substance Use Disorders | 1 | CTD_human |
| Tgene | ETV6 | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
| Tgene | ETV6 | C0236969 | Substance-Related Disorders | 1 | CTD_human |
| Tgene | ETV6 | C0238463 | Papillary thyroid carcinoma | 1 | ORPHANET |
| Tgene | ETV6 | C0376544 | Hematopoietic Neoplasms | 1 | CTD_human |
| Tgene | ETV6 | C0376545 | Hematologic Neoplasms | 1 | CTD_human |
| Tgene | ETV6 | C0740858 | Substance abuse problem | 1 | CTD_human |
| Tgene | ETV6 | C1292769 | Precursor B-cell lymphoblastic leukemia | 1 | ORPHANET |
| Tgene | ETV6 | C1510472 | Drug Dependence | 1 | CTD_human |
| Tgene | ETV6 | C1832388 | Platelet Disorder, Familial, with Associated Myeloid Malignancy | 1 | ORPHANET |
| Tgene | ETV6 | C1838656 | Macrocytosis, Familial | 1 | CTD_human |
| Tgene | ETV6 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
| Tgene | ETV6 | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Tgene | ETV6 | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
| Tgene | ETV6 | C4316881 | Prescription Drug Abuse | 1 | CTD_human |
| Tgene | ETV6 | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
| Tgene | ETV6 | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies